Rare diseases
Investigational molecules
Locations
221 Crescent Street Suite 103a, 02453-3425, United States
Viridian Therapeutics Inc. concentrates its clinical research on thyroid eye disease and thyroid eye disease (TED), with studies spanning both active and chronic forms of the condition. The sponsor’s portfolio centers on therapies intended to address the signs and symptoms associated with orbital inflammation and related eye involvement.
Its research activity reflects sustained interest in treatment options for patients across different stages of TED.
Viridian Therapeutics Inc. runs clinical trials in conditions such as Endocrine ophthalmopathy, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study on the Effects of VRDN-003 for Patients with Active Thyroid Eye Disease
GermanyStudy of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease
FranceStudy on the Safety and Effectiveness of VRDN-001 for Patients with Thyroid Eye Disease
FranceStudy on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease
FranceStudy on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease
GermanyStudy of VRDN-001 for Patients with Thyroid Eye Disease Who Did Not Respond to Previous Treatment
CzechiaStudy on the Safety and Tolerability of VRDN-001 for Patients with Thyroid Eye Disease
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
